ALUNBRIG® (brigatinib) Shrank Tumors in Patients with ALK+ NSCLC That Had Spread to Other Parts of the Body
ALUNBRIG was evaluated in a broad range of patients, including those with ALK+ NSCLC that had spread to other parts of their body
The ALUNBRIG study included 275 patients with ALK+ NSCLC whose cancer had spread to other parts of their body.
137 patients received the recommended dosing regimen of 90 mg of ALUNBRIG orally once daily for 7 days, followed by an increase to 180 mg orally once daily. The other 138 patients received a different medicine called crizotinib.
- Patient ages ranged from 27 years to 89 years (average age was 59 years) and about half (55%) were female
- 58% of patients in the study had never smoked
Patients taking ALUNBRIG went twice as long without their disease getting worse or spreading versus those taking crizotinib
- BLINDED INDEPENDENT REVIEW COMMITTEE RESULTS
MEDIANa TIME TO PROGRESSION
aMedian is not the same as average. Please see glossary for definition.
- BLINDED INDEPENDENT REVIEW COMMITTEE
This was a group of independent researchers who objectively reviewed and evaluated the results from the trial.
OVERALL
Overall, 3 out of 4 patients had their tumors shrink in people taking ALUNBRIG (74%) versus crizotinib (62%).
101 of 137 patients (74%) taking ALUNBRIG achieved a response vs 85 of 138 patients (62%) taking crizotinib.
ALUNBRIG Helped Shrink Tumors in the Brain
The Blinded Independent Review Committee also evaluated a smaller group of 41 patients with brain metastases.
Overall, 14 of 18 patients (78%) achieved a response while taking ALUNBRIG vs 6 of 23 patients (26%) taking crizotinib
- 3 out of every 4 patients with cancer that spread to their brain saw their tumors shrink when they were treated with ALUNBRIG
Of the 14 patients in this smaller group who responded to treatment with ALUNBRIG...
More than half of all patients (9 out of 14) who responded to ALUNBRIG maintained that response for 2 years or longer
- Researchers could not estimate the results for the 6 patients who responded to treatment with crizotinib
People Reported a Better Quality of Life with ALUNBRIG
During the study, 131 people taking ALUNBRIG completed a quality of life questionnaire.
Results from the questionnaire showed that people receiving ALUNBRIG went THREE TIMES LONGER without the symptoms of their cancer getting worse compared to patients treated with crizotinib.
- This means that the average time to symptoms getting worse was 26.7 months for patients taking ALUNBRIG compared with 8.3 months for patients taking crizotinib
- The study measurement included how people functioned with the disease (physical, emotional and social functioning) and the severity of the symptoms they experienced (including fatigue, nausea, vomiting, appetite loss and constipation)
Every patient is different. Always talk to your doctor
if you have any questions about ALUNBRIG.
Glossary
Median-The middle number in a set of measurements arranged from lowest to highest.
The middle number in a set of measurements arranged from lowest to highest.
